SCHEMBL718259

SCHEMBL718259

NC(=O)N1CC[CH]CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5507778 0.97 ALDH1A1 (0.37)
SCHEMBL6607522 0.91 ALDH1A1 (0.34)
SCHEMBL2017204 0.84
Hydrochloric Acid SCHEMBL4714836 0.82 ALDH1A1 (0.32)
Hydrochloric Acid SCHEMBL3398659 0.82
SCHEMBL4756872 0.79 PDE4B (0.31)
SCHEMBL422638 0.78
SCHEMBL572569 0.78 ALDH1A1 (0.45)
SCHEMBL17025695 0.74 ITGB3 (0.33)
SCHEMBL302276 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112752756-B Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators 因赛特公司 2024-06-25 CN claimed
US-20230357255-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2023-11-09 US claimed
EP-4219492-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2023-08-02 EP claimed
CN-109705090-B Tartaric acid addition salts of 3, 4-disubstituted 1H-pyrazole compounds and crystalline forms thereof 上海君实生物医药科技股份有限公司 2023-06-20 CN claimed
US-11673894-B2 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors INCYTE CORPORATION (US) 2023-06-13 US claimed
EP-3790877-B1 TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS INCYTE CORP (US) 2023-03-01 EP claimed
US-20220348594-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2022-11-03 US claimed
US-20210139485-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2021-05-13 US claimed
CN-112752756-A Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators 因赛特公司 2021-05-04 CN claimed
US-20210115068-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2021-04-22 US claimed
EP-1432702-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS RAF INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2006-08-16 EP claimed
WO-2005090348-A1 PYRAZOLO ’3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS GLAXO GROUP LIMITED (GB) 2005-09-29 WO claimed
WO-2005058892-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 WO claimed
EP-1495020-A1 N-(MORPHOLIN-2YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2005-01-12 EP claimed
EP-1487454-A1 MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY A HETEROCYCLYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS GLAXO GROUP LIMITED (GB) 2004-12-22 EP claimed
WO-2003082295-A1 MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY A HETEROCYCLYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS GLAXO GROUP LIMITED (GB) 2003-10-09 WO claimed
WO-2003082863-A1 N-(MORPHOLIN-2YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 WO claimed
EP-1021448-B1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS SCHERING CORP (US) 2003-05-02 EP claimed
EP-1021448-A1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS SCHERING CORPORATION (US) 2000-07-26 EP claimed
WO-1998015556-A1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS SCHERING CORPORATION (US) 1998-04-16 WO claimed